Biomerica, Inc. (BMRA)
NASDAQ: BMRA · Real-Time Price · USD
2.750
-0.070 (-2.48%)
At close: Sep 5, 2025, 4:00 PM
2.710
-0.040 (-1.45%)
After-hours: Sep 5, 2025, 7:59 PM EDT
Biomerica Revenue
In the fiscal year ending May 31, 2025, Biomerica had annual revenue of $5.31M, down -1.92%. Biomerica had revenue of $749.00K in the quarter ending May 31, 2025, a decrease of -32.89%.
Revenue (ttm)
$5.31M
Revenue Growth
-1.92%
P/S Ratio
1.19
Revenue / Employee
$82,984
Employees
64
Market Cap
7.74M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
May 31, 2025 | 5.31M | -104.00K | -1.92% |
May 31, 2024 | 5.42M | 76.00K | 1.42% |
May 31, 2023 | 5.34M | -13.53M | -71.71% |
May 31, 2022 | 18.87M | 11.67M | 162.13% |
May 31, 2021 | 7.20M | 506.32K | 7.57% |
May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
May 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
May 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
BMRA News
- 3 days ago - United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® Kidney Test for Home Use - GlobeNewsWire
- 7 days ago - Biomerica Reports Fiscal 2025 Year End Results - GlobeNewsWire
- 23 days ago - United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® Ulcer Test for Home Use - GlobeNewsWire
- 2 months ago - InFoods IBS receives CPT® Proprietary Laboratory Analysis (PLA) Code - GlobeNewsWire
- 2 months ago - Clinical Diagnostics Industry Leader Scott Madel Joins Biomerica's Team as Chief Commercial Officer - GlobeNewsWire
- 3 months ago - Biomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair - GlobeNewsWire
- 3 months ago - Biomerica's inFoods® IBS Clinical Study Results Published in June Issue of Gastroenterology - GlobeNewsWire
- 3 months ago - Biomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods® IBS using a First of Its Kind Real-Time IBS Patient Feedback System - GlobeNewsWire